このページの翻訳は実験的なもので、現在開発中です。お待ちしております!
Cardiff Oncology マネジメント
マネジメント 基準チェック /34
Cardiff Oncology'sの CEO はMark Erlanderで、 May2020年に任命され、 の在任期間は 4.08年です。 の年間総報酬は$ 1.55Mで、 38.4%給与と61.6%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.055%を直接所有しており、その価値は$ 65.37K 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と9.8年です。
主要情報
Mark Erlander
最高経営責任者
US$1.5m
報酬総額
CEO給与比率 | 38.4% |
CEO在任期間 | 4.1yrs |
CEOの所有権 | 0.05% |
経営陣の平均在職期間 | 2.4yrs |
取締役会の平均在任期間 | 9.8yrs |
経営陣の近況
Recent updates
We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely
Jun 19Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24Cardiff Oncology, Inc. (NASDAQ:CRDF) Analysts Are Reducing Their Forecasts For Next Year
Dec 02Cardiff Oncology: A Breakout Darkhorse In The Booming K-Ras Market
Nov 24CEO報酬分析
日付 |
---|